Meeting
2022 ASCO Annual Meeting
Comparison of survival outcomes of patients with newly diagnosed glioblastoma treated with standard chemoradiation in and outside of clinical trials.
Authors
Rifaquat Rahman
Dana-Farber/Brigham and Women's Cancer Center, Boston, MA
Rifaquat Rahman , Gilbert Youssef , Steffen Ventz , Robert Redd , Jon McDunn , William Louv , Brian Michael Alexander , Patrick Y. Wen , Lorenzo Trippa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2051)
DOI
10.1200/JCO.2022.40.16_suppl.2051
Abstract #
2051
Poster Bd #
389
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
First Author: Michael Weller
Poster
2011 ASCO Annual Meeting
A population-based study of glioblastoma multiforme (GBM) in the new stupp paradigm: Have we improved outcome?
First Author: Z. Lwin
Poster
2023 ASCO Annual Meeting
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
First Author: Paul James Mulholland
Poster
2016 ASCO Annual Meeting
Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.
First Author: Olivier L. Chinot